Indian stocks: Visit www.stage2stocks.com →

Alector, Inc.

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Alector is in Stage 2, the uptrend phase, now in week 4 (since Sep 28, 2026). It closed at $1.83, 32.7% below its 52-week high and below its 200-day average, which is rising.

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. More about the company

$1.83
-2.14% today
$204M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ALEC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 18w
S4 17w
S4 36w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 18w → S1 5w → S2 6w → S3 2w → S4 17w → S1 10w → S4 36w → S1 11w → S2 10w → S3 6w → S4 6w → S1 5w → S2 12w → S3 5w → S4 7w → S1 4w → S2 4w current
Total tracked: 165 weeks across 17 stage runs.

ALEC among Biotechnology326th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…326ALECStage 2 · wk 427−9.4%
vs 52W High
-32.7%
$1.14 lo$2.72 hi
32.7% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
-9.6%
200 DMA: $2.02 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.40x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-9.4%
3M
+23.6%
6M
-24.7%
YTD
+19.6%
1Y
-43.0%
Scan Membership
Breakout Watch
Latest: 2024-01-26
5 appearances in last 60 days. First seen: 2020-01-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 4 · Vol 0.40x
2026-10-21S2
Wk 4 · Vol 0.30x
2026-10-20S2
Wk 4 · Vol 0.54x
2026-10-19S2
Wk 4 · Vol 0.64x
2026-10-16S2
Wk 3 · Vol 1.39x
2026-10-15S2
Wk 3 · Vol 0.44x
2026-10-14S2
Wk 3 · Vol 0.80x
2026-10-13S2
Wk 3 · Vol 0.79x
2026-10-12S2
Wk 3 · Vol 0.45x
2026-10-09S2
Wk 2 · Vol 0.89x
2026-10-08S2
Wk 2 · Vol 1.90x
2026-10-07S2
Wk 2 · Vol 1.19x
Moving averages & range
50 DMA
$2.09
200 DMA
$2.02
52W High
$2.72
52W Low
$1.14
5D Low
$1.83
Resistance levels (recent highs)
20d High
$2.08
60d High
$2.72
120d High
$2.72
250d High
$2.72
Next resistance
+13.7%
to 20d High
ROE
-385.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -20.6

Alector: quick answers

What stage is Alector in?

As of Oct 22, 2026, Alector (ALEC) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Alector in an uptrend?

Yes. Alector is in a Stage 2 uptrend. It trades 9.6% below its 200-day average, which is rising.

How far is Alector from its 52-week high?

Alector closed at $1.83 on Oct 22, 2026, 32.7% below its 52-week high of $2.72. Its 52-week low is $1.14.

How has Alector performed over the past year?

As of Oct 22, 2026, Alector is down 43.0% over the past year and up 19.6% so far in 2026.

Which sector and industry is Alector in?

Alector is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.